BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 int ...

有很多习惯，我们知道它对健康不利，但总会"不自觉"地放纵自己，比如熬夜、吃高热量的垃圾食品等等—— 但其实，这些坏习惯对我们健康的危害比想象中更严重。 首先，《Nature》子刊的一篇研究论文表明，一系列环境因素，包括生活方式 （例如吸烟、运动锻炼） 和生活条 件，对健康和衰老的影响比遗传因素的影响更大。 其次，睡眠作为人体最基本的生理需求之一，其质量的高低直接关系到免疫系统的功能和整体健康状态。一项 发表在《The Journal of Immunology》的研究指出，即使是短暂的一夜不睡，也会对免疫系统产生显著的负面影 响，使单核细胞的特征发生改变，进而引发慢性炎症和相关疾病的风险增加。 最后，饮食习惯对健康的影响也不容小觑。另一项发表在《Nature》子刊的研究显示，即使是短期的高热量饮 食，也会对大脑结构和功能产生长期的不良影响。 这些研究为我们提供了关于生活习惯对健康影响的有力证据，同时，它们不仅为我们敲响了警钟，也为改善健 康提供了新的方向。 生活方式的影响，远超基因 虽然人类的人均寿命已经突破了80岁，但是我们关于衰老的认知仍然在被不断颠覆——2025年2月19日，牛 津大学的研究人员在国际顶 ...

Group 1 - Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells for cancer and autoimmune disease treatment [1][3] - The company will host a conference call and webcast on April 15, 2025, at 4:30 p.m. ET to provide a business update [1][2] - Cue Biopharma's proprietary platform, Immuno-STAT™, is designed to harness the body's immune system by selectively modulating disease-specific T cells without broad systemic immune modulation [3] Group 2 - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology, protein engineering, and clinical development of protein biologics [4] - Investors can access the conference call via specific phone numbers and a webcast link, with the archived version available for 30 days [2]

-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 -- -- Cash and cash equivale ...

Core Insights - Q32 Bio Inc. announced the presentation of Phase 2a Part A results of bempikibart for alopecia areata at the 2025 AAD Annual Meeting, highlighting its potential in treating severe cases of the disease [1][2] Group 1: Clinical Trial Details - The SIGNAL-AA Phase 2a clinical trial is a randomized, placebo-controlled study evaluating bempikibart, a fully human anti-IL-7Rα antibody [1][4] - The oral presentation will take place on March 8, 2025, from 10:36 a.m. to 10:48 a.m. ET at Chapin Theater, Level II [2] Group 2: Company Overview - Q32 Bio is a clinical stage biotechnology company focused on developing biologic therapeutics aimed at restoring immune homeostasis in autoimmune and inflammatory diseases [3][4] - Bempikibart is being evaluated for its ability to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling pathways, which are implicated in various autoimmune diseases [4]